MRK241018C116000
- 0.01
- 0.000.00%
Merck & Co Newsroom
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Investors in Merck (NYSE:MRK) Have Seen Respectable Returns of 48% Over the Past Three Years
"Trump Trade" is restarting, what are the differences?
The new change of the "Trump trade" is that US technology stocks are more resilient, energy stocks are weaker, US bond yields are falling instead of rising, and gold is performing stronger. Ping An Securities believes that the current situation is still in a stalemate, and it is uncertain how far the "Trump trade" can go.
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios
Express News | Merck China President Muqiqi He: Green transformation requires robust incentive mechanisms and systems.
Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?
Express News | Merck Pharmaceuticals: The results of mid-to-late-stage clinical trials indicate that the experimental therapy for Respiratory Syncytial Virus (RSV) helps protect infants and paves the way for potential regulatory approval.
Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
Merck Says Experimental RSV Treatment Protected Infants in Trial, Paving Way for Potential Approval
Merck's Posts More Positive Clesrovimab RSV Candidate Study Data
Express News | Merck’s Clesrovimab (Mk-1654), an Investigational Respiratory Syncytial Virus (Rsv) Preventative Monoclonal Antibody, Significantly Reduced Incidence of Rsv Disease and Hospitalization in Healthy Preterm and Full-Term Infants
Express News | Merck: In Phase 2B/3 Trial Clesrovimab Reduced Rsv-Associated Lower Respiratory Infection Hospitalizations by Over 90% Through 5 Months
Merck (MRK): Promising Long-Term Stock With Strategic Acquisitions
Merck & Co Analyst Ratings
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein initiates coverage on eli lilly and co, gilead sciences, and amgen with an "outperform" rating. Bernstein stated that the bullish ratings on gilead and amgen are based on optimistic expectations for revenue growth from key assets from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it uses the cash generated from weight loss drugs", eli lilly and co is ready to leverage a diversified investment portfolio and drive growth through weight loss drugs. In addition, Bern
Here's What to Expect From Merck & Co.'s Next Earnings Report
Express News | Merck & Co Inc : Bernstein Initiates Coverage With Market-Perform Rating; Target Price $115
Trump, big comeback! Is the 'Trump trade' making a comeback?
"Trump trade" is gaining momentum. The long-dormant "Trump trade" seems to be making a comeback. Among them, the stock price of the Trump Media and Technology Group has been soaring, with the stock price skyrocketing over 15.5% on October 16th Eastern Time, a cumulative increase of over 166% compared to the September low. At the same time, the "Trump trade" is boosting the prices of bitcoin and the US dollar. On the news front, there has been a major turnaround in Trump's election prospects. As of October 16th local time, a latest nationwide poll released by Fox News shows Trump leading Harris by 50% to 48%, which is different from September.
No matter who takes over the White House, financial trading activities will pick up.
Whether it's Donald Trump or Kamala Harris taking office in the White House, the market generally expects financial trading activities to heat up, bringing good news to Citigroup, Goldman Sachs, JPMorgan, and other major banks.